• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

Matt Warman, MD

Professor, Department of Genetics, Harvard Medical School

Harriet M. Peabody Professor of Orthopaedic surgery, Department of Orthopaedic Surgery, Harvard Medical School

Professor, Genetics, Harvard Medical School

Director, Orthopaedic Research Laboratories, Boston Children's Hospital

Contact Info

Matthew Warman
Boston Children's Hospital
Department of Orthopaedics

Boston, MA, 02493
Phone: 617-919-2371


Linda Fucci
Boston Children's Hospital
Phone: 617-919-4668

DF/HCC Program Affiliation

Cancer Cell Biology
Cancer Genetics

Lab Website

Warman Lab Page

Research Abstract

Work in the Warman lab focuses on understanding biologic pathways that affect the patterning, growth, and maintenance of the skeletal system. Our long-term goal is to improve human skeletal health. We initially identified biologic pathways through the study of patients and their families who have well-defined heritable disorders affecting bones and joints; using this approach we determined that the Wnt signaling pathway is a key regulator of bone mass acquisition, the natriuretic peptide signaling pathway is an important effector of postnatal linear growth, and the glycoprotein lubricin is the principal boundary lubricant in articulating joints. We are currently employing biochemical, cellular, and model organism approaches to precisely delineate the roles of these pathways and proteins during growth and homeostasis. We have also extended our patient-oriented research to include families with unique syndromes and patients with sporadically occurring skeletal diseases. This has enabled us to identify a missense mutation in the nuclear pore protein, RANBP2, as a susceptibility locus for a novel, environmentally triggered, neurodegenerative disease, and several de novo microduplications or microdeletions as causes of sporadically occurring malformations that affect the patterning of the limbs and spine. These latter studies serve as an entrée toward our ultimate goal of being able to provide truly “personalized” genetic medicine to every patient with skeletal disease in whom a genetic contribution is suspected.


View All Publications